Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (April 2018)
27 slides from Adalta's investor presentation, Apr 18, 2018
Slide 1: Introducing AD-214
For personal use only Introducing AD-214 April 2018 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: AdAlta Limited drug discovery and development company
For personal use only AdAlta Limited (ASX:1AD) is a drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. 3
Slide 4: AdAlta (1AD) investment summary
AdAlta (1AD) investment summary For personal use only Initial focus on treating fibrosis – high unmet medical need Advanced lead fibrosis drug candidate AD-214 with significant pre-clinical validation New molecule, AD-214 leverages all work from AD-114 to deliver enhanced activity and significantly
Slide 5: Financial position
Financial position For personal use only Key financial details Share performance (last 12 months) ASX code 1AD Share price (10th April 2018) AU$0.325 Market capitalisation AU$33m Shares on issue* 101,845,845 Escrowed shares (August 2018) 24,000,000 Options on issue 4,090,866 Current cash (31 March 2
Slide 6: Extensive support from institutional investors and HNWs
Extensive support from institutional investors For personal use only and HNWs Australian based venture capital $40m Top 20 shareholders 83% fund 64% institutional shareholders 10% HNWs with >500K shares $27b under management, global each equities investor 5% founding academic institutions Australian
Slide 7: Management and Board in place to deliver strategy
Management and Board in place to For personal use only deliver strategy Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Extensive experience in raising equity, contract and CEO of investment Company NewStar Ventures grant funding Managing Director of acquired antibody compa
Slide 8: Scientific Advisory Board
Scientific Advisory Board For personal use only Internationally recognised with proven track record of drug development Dr Mick Foley, AdAlta CSO John Westwick: pulmonary drug Expert in phage display discovery and development NIH, NHMRC, ARC, Gates funding and over 70 Over 14 years experience at Nov
Slide 9: From single domain antibody to AD-214
From single domain antibody to AD-214 For personal use only When combined, the i-body and Fc Fragment create a superior drug, with improved therapeutic benefit for patients and for potential commercial partners Monoclonal Antibody AD-214 i-body binds to CXCR4 to have anti- fibrotic activity Fc Fragm
Slide 10: Fc Fusion – well understood, high value drugs
Fc Fusion – well understood, high value drugs For personal use only Fc-Fusion proteins join the fragment (Fc) domain of an antibody with another protein domain or peptide to create a unique molecule with great therapeutic potential 11 Fc-Fusion based products approved by the FDA Straightforward, wel
Slide 11: AD-214: superior drug candidate
AD-214: superior drug candidate For personal use only Enhanced binding – Due to dual binding of two i-body molecules, enhanced binding to drug target CXCR4 – No change to proposed mechanism of action; i-body binds to CXCR4 with unique activity compared to other CXCR4 antagonists – Same active molecu
Slide 12: Leveraging AD-114 for a superior molecule
Leveraging AD-114 for a superior molecule For personal use only AD-114 AD-214 A B G High affinity binding to CXCR4 ✓ ✓✓✓ Specificity to CXCR4 ✓ ✓ Unique pharmacology compared ✓ ✓ to other CXCR4 antagonists No stem cell mobilisation No stem cell mobilisation H Half-life 24hrs in non human Significant
Slide 13: AD-214 for the treatment of IPF
AD-214 for the treatment of IPF For personal use only Extensive pre-clinical data package with i-body demonstrates positive in vitro and in vivo in models of IPF Normal In the bleomycin mouse model of fibrosis the anti-CXCR4 i- lung tissue body has several effects in both therapeutic and prophylacti
Slide 14: CXCR4 novel target for treatment of IPF
CXCR4 novel target for treatment of IPF For personal use only Significant literature to support hypothesis CXCR4 of Normal human Diseased IPF the involvement of CXCR4 in fibrosis lung tissue lung tissue IPF diseased lung tissue has increased CXCR4 expression compared with normal lung tissues AD-214
Slide 15: Market opportunity for IPF
Market opportunity for IPF For personal use only Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease THE STATISTICS People living with IPF 300,000 People die from IPF every year 40,000 Median length of survival after IPF diagnosis 3.8 years 15
Slide 16: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments For personal use only Fibrosis assets acquired at an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-15 Adheron SDP051 Roche $105M upfront, plus SDP-51 at end of Phase I for IPF Therap
Slide 17: IPF Phase II readouts generate $1.4 billion market value
IPF Phase II readouts generate $1.4 billion market For personal use only value (NASDAQ:FGEN) $869 million added to its market cap on announcement (7 August 2017) of meeting primary endpoint in Phase IIb study Pamrevlumab (FG-3019) 103 patients 48 weeks (Euronext:GLPG; NASDAQ:GLPG) $555 million added
Slide 18: AD-214 has broad application in treating fibrosis
AD-214 has broad application in treating fibrosis For personal use only AdAlta data shows that its lead anti- CXCR4 i-body candidate can improve fibrosis across a range of fibrotic diseases LUNG: Idiopathic Pulmonary Fibrosis Lung Eye Liver EYE: Wet Age Related Macular Degeneration IPF Wet-AMD & PVR
Slide 19: AD-214 development: key milestones
AD-214 development: key milestones For personal use only 2018 2019 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Manufacturing Toxicology Partnering of lead studies candidate based on other Phase I benchmark deals Publication of data Development of i-body pipeline BD and partnerships 19
Slide 20: i-body platform
i-body platform For personal use only Two longlong loops called “CDR” loops called Each unique i-bodyEach unique i-body 11 1 212 2Tworegions 3 Two loops 2 called CDRlong Two“CDR” 3 loops are 3Each“CDR” unique i-body 3 Each i-body has different are engineered regions are engineeredregions has ontoare
Slide 21: i-bodies combine benefits of small molecules and conventional antibodies
i-bodies combine benefits of small molecules and For personal use only conventional antibodies Long loop that enables access to Small Conventional AdAlta novel drug targets Molecule Antibody i-body High selectivity-specificity Low toxicity: no off target effects Cavity binding and new epitopes Stabi
Slide 22: AdAlta business model – strategy to create value
AdAlta business model – strategy to For personal use only create value Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 23: Market benchmarks
Market benchmarks For personal use only Fibrosis Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS lead AD-114 $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen April-16 with Abbvie Feb-18 with Seattle Genetics Feb-18 w
Slide 24: Significant achievements 2017/18
Significant achievements 2017/18 For personal use only ✓ Orphan Drug Designation (US FDA) of AdAlta i-body for treatment of IPF ✓ Completion of additional pre-clinical animal models in diseases of the lung, kidney, skin; strengthening broad anti-fibrotic data package of anti-CXCR4 i-body ✓ Publicati
Slide 25: Expected news flow
Expected news flow For personal use only H1 2018 ✓ Publication of AD-114 data in Scientific Reports demonstrating i-body application of pulmonary fibrosis with human tissue and animal model data ✓ Investor and analyst briefing detailing application of the i-body for the undruggable targets such as G
Slide 26: AdAlta summary
AdAlta summary For personal use only Initial focus on treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases - high unmet clinical need AD-214 has significant pre-clinical validation demonstrating broad anti-fibrotic and anti- inflammatory effects as well as safety AD-214 orphan dr
Slide 27: Contact us
For personal use only Contact us: Sam Cobb, CEO s.cobb@adalta.com.au www.adalta.com.au 27